Marinomed Biotech AG reports first‑half 2025 financial results and executes a capital‑increase programme
Marinomed Biotech AG, the Vienna‑based biopharmaceutical company that specialises in patent‑protected immunological and antiviral therapies, announced its financial performance for the first half of 2025 on 17 September. The announcement, issued through the standard EU‑compliant channels of EQS‑News and the Vienna Stock Exchange, follows a capital‑increase transaction that closed on 16 September.
First‑half 2025 financial highlights
The company’s management report, published in the 2025 Half‑Year Financial Report, outlines the company’s business performance, research and development activities, and strategic outlook. While the release did not yet disclose specific revenue figures in the briefing excerpts, it confirmed that Marinomed has continued to advance its pipeline and maintain a steady cash‑flow position. The report also provides an overview of the company’s risk profile and the anticipated developments for the second half of the year, signalling ongoing investment in R&D to secure its competitive edge in the pharmaceutical sector.
Capital‑increase under exclusion of subscription rights
On 16 September, Marinomed resolved to raise additional capital through the issuance of 61 607 bearer shares, each with a nominal value of €0.00. The new shares were sold at a price of €17.50 per share, resulting in a gross capital infusion of approximately €1.08 million. The transaction excluded the statutory subscription rights of existing shareholders, effectively allowing the company to access fresh capital without diluting current ownership stakes.
The increase in share capital raises the company’s share count to 1 839 940, with the basic capital growing by €61 607. The proceeds are earmarked to support ongoing research projects, expand manufacturing capabilities, and potentially fund strategic acquisitions that could accelerate the commercialization of Marinomed’s therapeutic portfolio.
Market reaction and broader context
Marinomed’s share price closed at €19.60 on 16 September, well above its 52‑week low of €7 and close to its 52‑week high of €21. The company’s market capitalisation stands at roughly €34.9 million, reflecting the confidence of investors in its niche therapeutic focus and its recent financial disclosures.
The Vienna Stock Exchange’s ATX Prime index remained largely unchanged on the day of the announcement, indicating that Marinomed’s actions did not significantly alter overall market sentiment. Nevertheless, the company’s decision to raise capital and its ongoing R&D efforts are likely to be closely watched by analysts covering the health‑care sector, particularly those focused on biopharmaceutical innovation in Central Europe.
Outlook
With the capital‑increase in place, Marinomed is positioned to accelerate its development roadmap. The management report emphasises continued investment in immunological and antiviral platforms, aligning with the company’s stated mission to deliver patent‑protected therapies to patients across Austria. Investors and stakeholders should expect further disclosures in the second half of 2025, where the company will detail revenue outcomes, R&D milestones, and any strategic collaborations that may arise from the newly raised capital.
Marinomed’s commitment to a focused, technology‑driven pipeline, coupled with prudent financial management, suggests a stable trajectory as the firm navigates the competitive biopharmaceutical landscape.